The stock has a 36-month beta value of 2.29. Opinions on the stock are mixed, with 6 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CMPS is 64.05M, and at present, short sellers hold a 6.98% of that float. On February 21, 2025, the average trading volume of CMPS was 1.02M shares.
CMPS) stock’s latest price update
Compass Pathways Plc ADR (NASDAQ: CMPS)’s stock price has plunge by 2.42relation to previous closing price of 4.54. Nevertheless, the company has seen a 5.20% surge in its stock price over the last five trading sessions. businesswire.com reported 2025-02-18 that LONDON & NEW YORK–(BUSINESS WIRE)—- $CMPS #Biotech–Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter 2024 ending December 31, 2024, and provide an update on recent developments, on February 27th, 2025. Compass management will host a conference call at 8:00 am ET (1:00pm UK) on February 27, 2025. To access the call, please register in a.
CMPS’s Market Performance
Compass Pathways Plc ADR (CMPS) has seen a 5.20% rise in stock performance for the week, with a 24.66% gain in the past month and a -0.21% plunge in the past quarter. The volatility ratio for the week is 8.07%, and the volatility levels for the past 30 days are at 8.96% for CMPS. The simple moving average for the past 20 days is 6.87% for CMPS’s stock, with a -22.08% simple moving average for the past 200 days.
Analysts’ Opinion of CMPS
Many brokerage firms have already submitted their reports for CMPS stocks, with RBC Capital Mkts repeating the rating for CMPS by listing it as a “Outperform.” The predicted price for CMPS in the upcoming period, according to RBC Capital Mkts is $23 based on the research report published on July 23, 2024 of the previous year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see CMPS reach a price target of $30. The rating they have provided for CMPS stocks is “Overweight” according to the report published on April 01st, 2024.
Deutsche Bank gave a rating of “Buy” to CMPS, setting the target price at $16 in the report published on December 12th of the previous year.
CMPS Trading at 12.02% from the 50-Day Moving Average
After a stumble in the market that brought CMPS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.53% of loss for the given period.
Volatility was left at 8.96%, however, over the last 30 days, the volatility rate increased by 8.07%, as shares surge +22.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.48% upper at present.
During the last 5 trading sessions, CMPS rose by +7.22%, which changed the moving average for the period of 200-days by -44.44% in comparison to the 20-day moving average, which settled at $4.36. In addition, Compass Pathways Plc ADR saw 23.02% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CMPS starting from ATAI Life Sciences N.V., who sale 2,660,000 shares at the price of $6.05 back on Sep 26 ’24. After this action, ATAI Life Sciences N.V. now owns 6,905,774 shares of Compass Pathways Plc ADR, valued at $16,093,000 using the latest closing price.
Malievskaia Ekaterina, the 10% Owner of Compass Pathways Plc ADR, sale 8,900 shares at $7.91 during a trade that took place back on May 21 ’24, which means that Malievskaia Ekaterina is holding 3,931,687 shares at $70,379 based on the most recent closing price.
Stock Fundamentals for CMPS
Current profitability levels for the company are sitting at:
- -45.76 for the present operating margin
- 0.47 for the gross margin
The net margin for Compass Pathways Plc ADR stands at -39.27. The total capital return value is set at -0.76. Equity return is now at value -64.99, with -53.09 for asset returns.
Based on Compass Pathways Plc ADR (CMPS), the company’s capital structure generated 0.14 points at debt to capital in total, while cash flow to debt ratio is standing at -3.23. The debt to equity ratio resting at 0.17. The interest coverage ratio of the stock is -37.61.
Currently, EBITDA for the company is -123.8 million with net debt to EBITDA at 1.18. When we switch over and look at the enterprise to sales, we see a ratio of 37.36. The receivables turnover for the company is 0.28for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.91.
Conclusion
To sum up, Compass Pathways Plc ADR (CMPS) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.